What is the equity of Evotec this year?
Evotec has equity of 1.12 B EUR this year.
Evotec Equity 2024
Evotec Equity
1.12 B EUR
Ticker
EVT.DE
ISIN
DE0005664809
WKN
566480
In 2024, Evotec's equity was 1.12 B EUR, a -5.67% increase from the 1.19 B EUR equity in the previous year.
Evotec Aktienanalyse
What does Evotec do?
Evotec SE is a biotechnology company based in Hamburg that specializes in the development of drug compounds for the pharmaceutical and biotech industries. The company was founded in 1993 as part of a research project at the University of Hamburg and has since become one of the leading drug discovery and development companies globally. Evotec's business model is based on collaborating with its customers, primarily large pharmaceutical companies, to develop new and innovative drugs. Evotec offers its extensive expertise in drug discovery and acts as a service provider. The company has modern laboratories equipped with state-of-the-art scientific methods and technologies. Customers benefit from the scientists' years of experience and collaboration with renowned academic institutions worldwide. Evotec operates in the Discovery, Development, and Manufacturing segments, providing a wide range of services to its customers. In the Discovery segment, the focus is on identifying drug candidates and preclinical development of drugs using advanced technologies and research methods. In the Development segment, Evotec supports its customers in the planning, execution, and analysis of clinical trials. The close collaboration with customers allows Evotec's scientists to respond quickly and effectively to feedback and requirements. The Manufacturing segment involves the industrial production of drugs. Evotec offers a broad range of products, including both its own and customer-requested drug compounds. One example is the drug DiaPep277 for the treatment of Type 1 diabetes. DiaPep277 was developed by Evotec in collaboration with Israeli company Andromeda Biotech and is now distributed by Teva Pharmaceuticals. Another example is the drug EVT307, which was developed by Evotec in collaboration with pharmaceutical company Boehringer Ingelheim and is currently being tested in Phase II clinical trials for the treatment of schizophrenia. Evotec's success is also based on its expertise in the production of small molecules. Small molecules are drug compounds characterized by their small size and highly specific binding to target proteins. In contrast, the production of large molecules such as antibodies or biologics is more complex and expensive in development due to their size. Evotec's success story continues: In 2019, the company achieved record results, increasing its revenue by 23 percent to 446.4 million euros. The number of employees has also steadily grown in recent years and now exceeds 3,000 employees worldwide. Evotec is considered one of the most successful biotechnology companies in Europe today. Evotec ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Evotec's Equity
Evotec's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Evotec's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Evotec's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Evotec's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Evotec’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Evotec stock
What was the equity of Evotec compared to the previous year?
The equity of Evotec has increased/decreased by -5.67% decreased compared to the previous year.
What impact does a high equity have on investors of Evotec?
A high equity is advantageous for investors of Evotec as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Evotec?
A low equity can be a risk for investors of Evotec, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Evotec affect the company?
An increase in equity of Evotec can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Evotec affect the company?
A reduction in equity of Evotec can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Evotec?
Some factors that can affect the equity of Evotec include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Evotec so important for investors?
The equity of Evotec is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Evotec take to change the equity?
To change equity, Evotec can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Evotec pay?
Over the past 12 months, Evotec paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Evotec is expected to pay a dividend of 0 EUR.
What is the dividend yield of Evotec?
The current dividend yield of Evotec is .
When does Evotec pay dividends?
Evotec pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Evotec?
Evotec paid dividends every year for the past 0 years.
What is the dividend of Evotec?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Evotec located?
Evotec is assigned to the 'Health' sector.
Wann musste ich die Aktien von Evotec kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Evotec from 10/4/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.
When did Evotec pay the last dividend?
The last dividend was paid out on 10/4/2024.
What was the dividend of Evotec in the year 2023?
In the year 2023, Evotec distributed 0 EUR as dividends.
In which currency does Evotec pay out the dividend?
The dividends of Evotec are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Evotec stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank
Andere Kennzahlen von Evotec
Our stock analysis for Evotec Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Evotec Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
